Cargando…

Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open‐Label, Randomized Study

In children aged ≤4 years, the relative bioavailability of lamivudine oral solution was 37% lower than that of a tablet formulation. An open‐label, four‐way crossover study was conducted in healthy adults to evaluate the effect of sorbitol, a common liquid excipient, on the pharmacokinetics of lamiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adkison, Kimberly, Wolstenholme, Allen, Lou, Yu, Zhang, Zhiping, Eld, Amy, Perger, Teodora, Vangerow, Harald, Hayward, Katy, Shaefer, Mark, McCoig, Cynthia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836851/ https://www.ncbi.nlm.nih.gov/pubmed/29150845 http://dx.doi.org/10.1002/cpt.943

Ejemplares similares

Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials
por: Nan, Cassandra, et al.
Publicado: (2018)

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection
por: Quercia, Romina, et al.
Publicado: (2018)

Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants
por: Singh, Rajendra P., et al.
Publicado: (2021)

Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine
por: Dumitrescu, Teodora Pene, et al.
Publicado: (2019)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min
por: Ross, Lisa L., et al.
Publicado: (2019)

Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials
por: Nan, Cassandra, et al.
Publicado: (2017)

Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2012)

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
por: Gitta, PK, et al.
Publicado: (2010)

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
por: Rodríguez, Manuel, et al.
Publicado: (2017)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

Sorbitol reduction via govorestat ameliorates synaptic dysfunction and neurodegeneration in sorbitol dehydrogenase deficiency
por: Zhu, Yi, et al.
Publicado: (2023)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Pharmacokinetics of transdermal buprenorphine patch in the elderly
por: Al-Tawil, Nabil, et al.
Publicado: (2012)

Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial
por: Wohl, David A., et al.
Publicado: (2014)

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
por: D'Amico, Ronald, et al.
Publicado: (2020)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy
por: Yang, Fu-Qiang, et al.
Publicado: (2017)

Effect of chewing gums with xylitol, sorbitol and xylitol-sorbitol on the remineralization and hardness of initial enamel lesions in situ
por: Tuncer, Duygu, et al.
Publicado: (2014)

Preclinical Pharmacokinetics of Lamivudine and Its Interaction with Schisandra chinensis Extract in Rats
por: Li, Chi-Lin, et al.
Publicado: (2020)

2043: Pharmacokinetic prediction of paclitaxel-induced peripheral neuropathy
por: Hertz, Daniel L., et al.
Publicado: (2018)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
por: Shoaf, Susan E, et al.
Publicado: (2014)

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors
por: Savelieva, Marina, et al.
Publicado: (2015)

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
por: Townsend, Robert W., et al.
Publicado: (2017)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
por: Kumar, Princy N, et al.
Publicado: (2009)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
por: Mehta, Rashmi, et al.
Publicado: (2020)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Xylitol and sorbitol effects on the microbiome of saliva and plaque
por: Rafeek, Reisha, et al.
Publicado: (2018)

Quaking Regulates Hnrnpa1 Expression through Its 3′ UTR in Oligodendrocyte Precursor Cells
por: Zearfoss, N. Ruth, et al.
Publicado: (2011)

Exogenous Sorbitol Application Confers Drought Tolerance to Maize Seedlings through Up-Regulating Antioxidant System and Endogenous Sorbitol Biosynthesis
por: Li, Jun, et al.
Publicado: (2023)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects
por: Perera, Vidya, et al.
Publicado: (2018)

An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects
por: Round, Patrick, et al.
Publicado: (2011)

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
por: Kielbasa, William, et al.
Publicado: (2013)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cr5lpj4b7klfmluu7bri42gkgt